decisionhealth Newsletters, Part B News - 2006 Issue 1 (January)
Extra IVIG payment too low
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare payment update related to intravenous immune globulin (IVIG) and why some stakeholders считают the additional payment may still be insufficient to support office-based treatment. It is relevant to physicians, hospital outpatient billing staff, coders, and reimbursement professionals following CMS fee schedule updates, IVIG pricing, and access-to-care concerns. The article also references market-rate comparisons, shifts in site of service, and CMS’s pending review of pricing data.
Why This Topic Matters
It helps readers understand a reimbursement change that may affect whether IVIG is offered in physician offices versus other care settings, and it provides context for monitoring CMS payment decisions and market pricing trends.
What You Will Learn
- How CMS updated payment guidance for IVIG-related billing
- Why stakeholders were concerned about the adequacy of the extra payment
- How IVIG pricing and site-of-service trends were influencing access to care
- What role market pricing review was expected to play in future payment decisions
Who Should Read This
- Physicians
- Medical coders
- Billing staff
- Reimbursement specialists
- Hospital outpatient revenue cycle teams
- Practice administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com